Dissecting the Evolution of Immunotherapy in Endometrial Cancer From ESMO 2025

Panelists discuss how advances in immunotherapy—particularly dostarlimab and pembrolizumab combinations—are transforming the frontline treatment landscape for advanced or recurrent endometrial cancer. Across the series, they explore evolving clinical evidence, toxicity management, guideline integration, and future research directions aimed at improving outcomes, personalizing care, and addressing ongoing unmet needs.

EP. 1: Molecular Subtypes of Endometrial Cancer

November 3rd 2025

Panelists discuss how molecular testing enables precise categorization of endometrial cancer into biologically distinct subtypes that guide prognosis, therapy selection, and future research direction.

EP. 2: Frontline Considerations for Immunotherapy in Endometrial Cancer

November 3rd 2025

Panelists discuss how patient and disease characteristics guide the selection of frontline immunotherapy regimens in recurrent or metastatic endometrial cancer.

EP. 3: RUBY Study Survival Analysis Informs Frontline Treatment Selection

November 10th 2025

Panelists discuss how survival data from the RUBY study highlight the benefits of dostarlimab plus chemotherapy in pMMR/MSS and older patient populations with advanced endometrial cancer.

EP. 4: Adverse Event and Quality-of-Life Considerations in Endometrial Cancer

November 10th 2025

Panelists discuss how careful management of adverse events and quality-of-life factors optimizes the safe use of dostarlimab plus chemotherapy in endometrial cancer.

EP. 5: Frontline Treatment Considerations in Endometrial Cancer

November 17th 2025

Panelists discuss how evolving immunotherapy combinations and NCCN guidelines shape frontline treatment selection for advanced or recurrent endometrial cancer.

EP. 6: Emerging Treatment Considerations for Endometrial Cancer

November 17th 2025

Panelists discuss how emerging therapies and biomarker-driven research are shaping the next wave of innovation in endometrial cancer treatment.

EP. 7: Unmet Needs and Future Research Focus for Endometrial Cancer

November 24th 2025

Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.